Methods of Identifying and Treating Progressive Colorectal Cancer
AssigneePresident and Fellows of Harvard College
InventorsPeter K. Sorger, Sandro Santagata, Jia-Ren Lin, Yu-An Chen
Life of this patent
Estimating the term…
Abstract
Methods are provided for identifying progressive colorectal cancer within an individual, and to methods of treating progressive colorectal cancer.
Claims29
A method comprising
- determining presence of pan-cytokeratin and E-cadherin in tumor cells and nontumor cells of a colorectal tissue sample obtained from a human patient by (i) contacting pan-cytokeratin with an antibody to pan-cytokeratin and detecting binding between pan-cytokeratin and the antibody to pan-cytokeratin and (ii) contacting E-cadherin with an antibody to E-cadherin and detecting binding between E-cadherin and the antibody to E-cadherin,
- determining levels of pan-cytokeratin and E-cadherin in the nontumor cells of the colorectal tissue sample and determining a ratio of pan-cytokeratin and E-cadherin in the nontumor cells of the colorectal tissue sample to establish a nontumor cell control baseline ratio,
- determining levels of pan-cytokeratin and E-cadherin in the tumor cells of the colorectal tissue sample and determining a ratio of pan-cytokeratin and E-cadherin in the tumor cells of the colorectal tissue sample to establish a tumor cell ratio, and
- comparing the tumor cell ratio to the nontumor cell control baseline ratio.
A method of distinguishing progressive cancer cells from nonprogressive cancer cells in a colorectal tissue sample from a human patient comprising
- determining presence of pan-cytokeratin and E-cadherin in tumor cells and nontumor cells of the colorectal tissue sample by (i) contacting pan-cytokeratin with an antibody to pan-cytokeratin and detecting binding between pan-cytokeratin and the antibody to pan-cytokeratin and (ii) contacting E-cadherin with an antibody to E-cadherin and detecting binding between E-cadherin and the antibody to E-cadherin,
- determining levels of pan-cytokeratin and E-cadherin in the nontumor cells of the colorectal tissue sample and determining a ratio of pan-cytokeratin and E-cadherin in the nontumor cells of the colorectal tissue sample to establish a nontumor cell control baseline ratio,
- determining levels of pan-cytokeratin and E-cadherin in the tumor cells of the colorectal tissue sample and determining a ratio of pan-cytokeratin and E-cadherin in the tumor cells of the colorectal tissue sample to establish a tumor cell ratio, and
- comparing the tumor cell ratio to the nontumor cell control baseline ratio,
- wherein a tumor cell ratio that is greater than the nontumor cell control baseline ratio indicates that the tumor cells are progressive colorectal cancer tumor cells, and
- wherein a tumor cell ratio that is substantially similar to the nontumor cell control baseline ratio indicates that the tumor cells are nonprogressive colorectal cancer tumor cells.
A method of detecting a pattern of biomarkers within a colorectal tissue sample of a human,
- wherein the colorectal tissue sample comprises tumor cells and nontumor cells,
- wherein the biomarkers comprise pan-cytokeratin and E-cadherin,
- comprising
- contacting the colorectal tissue sample with an antibody that identifies presence in the colorectal tissue sample of pan-cytokeratin,
- contacting the colorectal tissue sample with an antibody that identifies presence in the colorectal tissue sample of E-cadherin,
- acquiring pattern detection of the antibody that identifies presence in the colorectal tissue sample of pan-cytokeratin,
- acquiring pattern detection of the antibody that identifies presence in the colorectal tissue sample of E-cadherin.
A method of assaying for pan-cytokeratin and E-cadherin within a colorectal tissue sample of a human, wherein the colorectal tissue sample comprises tumor cells and nontumor cells comprising
- contacting the colorectal tissue sample with a first antibody that identifies presence in the colorectal tissue sample of pan-cytokeratin,
- contacting the colorectal tissue sample with a second antibody that identifies presence in the colorectal tissue sample of E-cadherin,
- determining amount of pan-cytokeratin relative to amount of E-cadherin within the tumor cells of the colorectal tissue sample,
- determining amount of pan-cytokeratin relative to amount of E-cadherin within the nontumor cells of the colorectal tissue sample.
A method of treating a human for progressive colorectal cancer comprising
- assaying for a ratio of pan-cytokeratin to E-cadherin within tumor cells of a colorectal tissue sample,
- assaying for a ratio of pan-cytokeratin to E-cadherin within nontumor cells of the colorectal tissue sample, and
- treating the human for progressive colorectal cancer when the ratio of pan-cytokeratin to E-cadherin within tumor cells of the colorectal tissue sample is higher than the ratio of pan-cytokeratin to E-cadherin within nontumor cells of the colorectal tissue sample.
A method of treating a human for progressive colorectal cancer comprising
- assaying for a ratio of pan-cytokeratin and E-cadherin within tumor cells of a colorectal tissue sample,
- assaying for a ratio of pan-cytokeratin and E-cadherin within nontumor cells of the colorectal tissue sample, and
- treating the human for progressive colorectal cancer when the ratio of pan-cytokeratin and E-cadherin within tumor cells of the colorectal tissue sample is different than the ratio of pan-cytokeratin and E-cadherin within nontumor cells of the colorectal tissue sample.
A combination of a labeled antibody to pan-cytokeratin and a labeled antibody to E-cadherin for the staining of a colorectal tissue sample.
A colorectal tissue sample from a human suspected of having colorectal cancer that is stained with a labeled antibody to pan-cytokeratin and a labeled antibody to E-cadherin.
A kit for use in an immunofluorescence assay comprising
- a first labeled antibody to pan-cytokeratin in a suitable liquid medium,
- a second labeled antibody to E-cadherin in a suitable liquid medium, and
- optional instructions for contacting the first labeled antibody to pan-cytokeratin and the second labeled antibody to E-cadherin to a tissue sample.
Dependencies are inferred from the claim text.